AGY Therapeutics Presents at IBC Target Validation Meeting

Apr 25, 2001, 01:00 ET from AGY Therapeutics, Inc.

    SOUTH SAN FRANCISCO, Calif., April 25 /PRNewswire/ -- AGY Therapeutics,
 Inc. (AGY) today announced that Thorsten Melcher, Ph.D., vice president of
 research at AGY, presented data at the IBC conference on Target Validation in
 San Diego, CA on Tuesday, April 24, 2001.
     "The work presented here demonstrates the power and utility of AGY's
 functional genomics platform to identify and validate critical pathways in
 stroke and other neurological disorders," said Karoly Nikolich, Ph.D., founder
 and chief executive officer of AGY.
     The presentation included data from collaborative studies between AGY and
 Dr. Tadeusz Wieloch at the Wallenberg Neuroscience Center (Lund, Sweden), in
 which neuroprotective genes were identified, functionally characterized and
 validated within a short time-frame.
     "AGY continues to validate many potential drug targets for stroke,
 Alzheimer's disease and other diseases to add to our drug discover efforts,"
 added Dr. Nikolich.
     AGY's proprietary imagine(TM) functional genomics platform enables the
 generation and collection of regulated genes from selected biological models.
 The imAGYne platform has been applied to the analysis of models of stroke and
 neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's
 disease and depression.
     AGY Therapeutics, Inc. is a privately held biopharmaceutical company
 focused on developing therapeutic products for the treatment of diseases of
 the central nervous system.  With its proprietary imagine(TM), imArrays(TM)
 and imFormatics(TM) platforms, AGY has built a unique knowledge base of the
 neuroprotective capacities and vulnerabilities of the nervous system.
     For additional information, please visit the Company's Web site at
 www.agyinc.com.
     This news release contains forward-looking statements about future
 research and development efforts.  These statements represent our judgment as
 of the date of this news release and are subject to risks and uncertainties
 that could cause actual results or events to differ materially from those
 expressed in such forward-looking statements.  In particular, we face risks
 and uncertainties that further research into these genes may not go forward as
 planned or that future scientific data on these genes may not provide
 supportive data for the diseases we are targeting.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X71925215
 
 

SOURCE AGY Therapeutics, Inc.
    SOUTH SAN FRANCISCO, Calif., April 25 /PRNewswire/ -- AGY Therapeutics,
 Inc. (AGY) today announced that Thorsten Melcher, Ph.D., vice president of
 research at AGY, presented data at the IBC conference on Target Validation in
 San Diego, CA on Tuesday, April 24, 2001.
     "The work presented here demonstrates the power and utility of AGY's
 functional genomics platform to identify and validate critical pathways in
 stroke and other neurological disorders," said Karoly Nikolich, Ph.D., founder
 and chief executive officer of AGY.
     The presentation included data from collaborative studies between AGY and
 Dr. Tadeusz Wieloch at the Wallenberg Neuroscience Center (Lund, Sweden), in
 which neuroprotective genes were identified, functionally characterized and
 validated within a short time-frame.
     "AGY continues to validate many potential drug targets for stroke,
 Alzheimer's disease and other diseases to add to our drug discover efforts,"
 added Dr. Nikolich.
     AGY's proprietary imagine(TM) functional genomics platform enables the
 generation and collection of regulated genes from selected biological models.
 The imAGYne platform has been applied to the analysis of models of stroke and
 neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's
 disease and depression.
     AGY Therapeutics, Inc. is a privately held biopharmaceutical company
 focused on developing therapeutic products for the treatment of diseases of
 the central nervous system.  With its proprietary imagine(TM), imArrays(TM)
 and imFormatics(TM) platforms, AGY has built a unique knowledge base of the
 neuroprotective capacities and vulnerabilities of the nervous system.
     For additional information, please visit the Company's Web site at
 www.agyinc.com.
     This news release contains forward-looking statements about future
 research and development efforts.  These statements represent our judgment as
 of the date of this news release and are subject to risks and uncertainties
 that could cause actual results or events to differ materially from those
 expressed in such forward-looking statements.  In particular, we face risks
 and uncertainties that further research into these genes may not go forward as
 planned or that future scientific data on these genes may not provide
 supportive data for the diseases we are targeting.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X71925215
 
 SOURCE  AGY Therapeutics, Inc.